Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Inflammatory bowel disease (IBD) is a non-communicable disease characterized by a chronic inflammatory process of the gut and categorized into Crohn’s disease and ulcerative colitis, both currently without definitive pharmacological treatment and cure. The unclear etiology of IBD is a limiting factor for the development of new drugs and explains the high frequency of refractory patients to current drugs, which are also related to various adverse effects, mainly after long-term use. Dissatisfaction with current therapies has promoted an increased interest in new pharmacological approaches using natural products. Coumarins comprise a large class of natural phenolic compounds found in fungi, bacteria, and plants. Coumarin and its derivatives have been reported as antioxidant and anti-inflammatory compounds, potentially useful as complementary therapy of the IBD. These compounds produce protective effects in intestinal inflammation through different mechanisms and signaling pathways, mainly modulating immune and inflammatory responses, and protecting against oxidative stress, a central factor for IBD development. In this review, we described the main coumarin derivatives reported as intestinal anti-inflammatory products and its available pharmacodynamic data that support the protective effects of these products in the acute and subchronic phase of intestinal inflammation.

Download Full-text

Leukocyte Traffic Blockade as a Therapeutic Strategy in Inflammatory Bowel Disease

Current Drug Targets ◽

10.2174/13894501113149990158 ◽

2013 ◽

Vol 14 (12) ◽

pp. 1490-1500 ◽

Cited By ~ 26

Author(s):

Giorgos Bamias ◽

David Clark ◽

Jesús Rivera-Nieves

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Therapeutic Strategy ◽

Inflammatory Bowel

Download Full-text

Preparation, characterization, and in vivo evaluation of anti-inflammatory activities of selenium nanoparticles synthesized by Kluyveromyces lactis GG799

Food & Function ◽

10.1039/d1fo01019k ◽

2021 ◽

Author(s):

Xiao fan Song ◽

Lei Qiao ◽

Shuqi Yan ◽

Yue Chen ◽

Xina Dou ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Kluyveromyces Lactis ◽

Selenium Nanoparticles ◽

Human Diseases ◽

In Vivo Evaluation ◽

Inflammatory Bowel ◽

Anti Inflammatory

Selenium (Se) as an essential micronutrient that has implications in human diseases, including inflammatory bowel disease (IBD), especially with respect to Se deficiencies. Recently, selenium nanoparticles (SeNPs) have attracted significant...

Download Full-text

Non Steroidal Anti-Inflammatory Drugs and Inflammatory Bowel Disease

Pharmaceuticals ◽

10.3390/ph3041084 ◽

2010 ◽

Vol 3 (4) ◽

pp. 1084-1092 ◽

Cited By ~ 26

Author(s):

Amir Klein ◽

Rami Eliakim

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Inflammatory Bowel ◽

Inflammatory Drugs ◽

Anti Inflammatory

Download Full-text

Food and Food Groups in Inflammatory Bowel Disease (IBD): The Design of the Groningen Anti-Inflammatory Diet (GrAID)

Nutrients ◽

10.3390/nu13041067 ◽

2021 ◽

Vol 13 (4) ◽

pp. 1067

Author(s):

Marjo J. E. Campmans-Kuijpers ◽

Gerard Dijkstra

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Food Group ◽

Dietary Guidelines ◽

Current Evidence ◽

Group Level ◽

Food Groups ◽

Inflammatory Bowel ◽

Anti Inflammatory

Diet plays a pivotal role in the onset and course of inflammatory bowel disease (IBD). Patients are keen to know what to eat to reduce symptoms and flares, but dietary guidelines are lacking. To advice patients, an overview of the current evidence on food (group) level is needed. This narrative review studies the effects of food (groups) on the onset and course of IBD and if not available the effects in healthy subjects or animal and in vitro IBD models. Based on this evidence the Groningen anti-inflammatory diet (GrAID) was designed and compared on food (group) level to other existing IBD diets. Although on several foods conflicting results were found, this review provides patients a good overview. Based on this evidence, the GrAID consists of lean meat, eggs, fish, plain dairy (such as milk, yoghurt, kefir and hard cheeses), fruit, vegetables, legumes, wheat, coffee, tea and honey. Red meat, other dairy products and sugar should be limited. Canned and processed foods, alcohol and sweetened beverages should be avoided. This comprehensive review focuses on anti-inflammatory properties of foods providing IBD patients with the best evidence on which foods they should eat or avoid to reduce flares. This was used to design the GrAID.

Download Full-text

P044 HIF1A IS A SWITCH IN THE PRO- VS ANTI-INFLAMMATORY FOXP3 GENE CIRCUITRY NETWORKS IMPLICATED IN INFLAMMATORY BOWEL DISEASE

Inflammatory Bowel Diseases ◽

10.1093/ibd/izy019.050 ◽

2018 ◽

Vol 24 (suppl_1) ◽

pp. S15-S16

Author(s):

Olga F Sarmento ◽

Phyllis A Svingen ◽

Mary R Sagstetter ◽

Michelle M Gonzalez ◽

Adebowale O Bamidele ◽

...

Keyword(s):

Inflammatory Bowel Disease ◽

Bowel Disease ◽

Foxp3 Gene ◽

Inflammatory Bowel ◽

Anti Inflammatory

Download Full-text

A moderately elevated soy protein diet mitigates inflammatory changes in gut and in bone turnover during chronic TNBS-induced inflammatory bowel disease

Applied Physiology Nutrition and Metabolism ◽

10.1139/apnm-2018-0514 ◽

2019 ◽

Vol 44 (6) ◽

pp. 595-605 ◽

Cited By ~ 4

Author(s):

Corinne E. Metzger ◽

S. Anand Narayanan ◽

David C. Zawieja ◽

Susan A. Bloomfield

Keyword(s):

Inflammatory Bowel Disease ◽

Bone Turnover ◽

Soy Protein ◽

Bowel Disease ◽

Protein Diet ◽

Trinitrobenzene Sulfonic Acid ◽

Inflammatory Bowel ◽

Anti Inflammatory ◽

The Impact ◽

Colitis Model

Inflammatory bowel disease is a condition that leads to gut pathologies such as abnormal lymphatic architecture, as well as to systemic comorbidities such as bone loss. Furthermore, current therapies are limited to low efficacy and incur side effects. Dietary interventions have been explored minimally, but may provide a treatment for improving gut outcomes and comorbidities. Indeed, plant-based soy protein has been shown to exert anti-inflammatory effects. Here, we tested the impact of a moderately elevated soy protein diet in a chronic, 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis model on gut and bone inflammatory-mediated pathophysiological adaptations. Colitis was induced by intrarectal administration of TNBS. Gut histopathology was scored, and lymphatic structural changes and the local inflammatory state were assessed via immunofluorescence. In addition, the effects of gut inflammation on bone turnover and osteocyte proteins were determined via histomorphometry and immunohistochemistry, respectively. The moderately elevated soy protein diet produced improvements in both colonic and bone tissues. In TNBS animals given the soy protein intervention, colon histological scores were reduced and the abnormal lymphatic architecture resolved. There were also improvements in bone formation and reduced bone resorption. In addition, TNBS increased inflammatory cytokines such as tumor necrosis factor-α and receptor activator of nuclear factor κ-B ligand in the gut and bone, but this was resolved in both tissues with the dietary soy protein intervention. The moderately elevated soy protein diet mitigated gut and bone inflammation in a chronic, TNBS-induced colitis model, demonstrating the potential for soy protein as a potential anti-inflammatory dietary intervention for inflammatory bowel disease.

Download Full-text